Plain-English translation of NCT07702825 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing whether a medication called a GLP-1 receptor agonist, combined with lifestyle changes, helps improve organ health in teenagers with severe obesity better than lifestyle changes alone. Researchers will use special MRI scans to measure fat in the body and around organs to see how well each approach works over 9 months.
Severe obesity in young people can damage organs like the liver and pancreas. Doctors want to know if this medication helps reverse that damage more effectively than diet and exercise alone, so they can offer teenagers the best possible treatment.
You likely qualify if…
You likely don't qualify if…
You will be assigned to one of two groups: one receiving the medication plus lifestyle support, or one receiving lifestyle support alone. At the start and again after 9 months, you'll have an MRI scan that takes pictures of your body to measure fat distribution and organ health — the scans are painless and take about 30–45 minutes. You'll also work with doctors and counselors on healthy eating and activity habits throughout the study.
AI-generated summary from trial data · Aug 15, 2026 · Not medical advice
United Kingdom
Enrollment target
~30 participants
Started
March 2026
Primary completion
December 2027
Age range
12 Years – 18 Years
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Anand Ramakrishnan, MD (Ped), MSc (Diab), PhD endo
Alder Hey Children's NHS Foundation Trust
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.